Therapeutic agent

Fluvoxamine

ModerateEvidence level
4Registered trials
2Conditions
0Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other
Safety
Nausea, insomnia, somnolence; significant CYP1A2 and CYP2C19 interactions. Avoid in combination with thioridazine, pimozide. Monitor for serotonin syndrome if combined with other serotonergics.
Dosing
50–100 mg/day (often 100 mg); short courses (10–15 days) in early studies; some PASC protocols 4–8 weeks.
Sigma-1 + SSRI; early COVID + some Long COVID data. 50-100mg. CYP interactions, GI/insomnia. Preliminary for select symptoms; not core fatigue/autonomic first choice.

Clinical Trials

4 trial(s) registered

NCT IDTitlePhaseStatus
NCT05874037Fluvoxamine for Long COVID-19Phase 2Completed
NCT07359482sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19Phase 3Recruiting
NCT04510194COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)Phase 3Completed
NCT06128967A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE TrialPhase 3Completed

Key Studies / References

  • See linked studies